Bioqual (OTCMKTS:BIOQ – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($2.81) EPS for the quarter, Zacks reports. Bioqual had a negative return on equity of 2.69% and a negative net margin of 2.27%.
Bioqual Price Performance
OTCMKTS BIOQ remained flat at $33.00 during trading hours on Monday. The company has a market capitalization of $29.37 million, a P/E ratio of -30.56 and a beta of -0.20. Bioqual has a 12-month low of $32.50 and a 12-month high of $43.55. The stock’s fifty day moving average is $32.68 and its 200 day moving average is $34.44.
Bioqual Company Profile
Bioqual, Inc is a contract research organization that provides preclinical biomedical research services to pharmaceutical, biotechnology and government customers. The company specializes in infectious disease research and uses laboratory and animal models to support the development and evaluation of vaccines, therapeutics and diagnostic products.
Its services have included studies involving HIV, hepatitis, influenza, COVID-19 and other infectious diseases, as well as immunology, pharmacology and toxicology research.
Further Reading
- Five stocks we like better than Bioqual
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
- AI Is Reshaping SaaS—These 2 Software ETFs Offer Different Ways to Play It
- Insiders Signal Deep Value In DICK’s Sporting Goods
Receive News & Ratings for Bioqual Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioqual and related companies with MarketBeat.com's FREE daily email newsletter.
